Date: 2017-01-02
Type of information: Termination of the agreement
Compound:
Company: Sanofi Pasteur (France) Merck&Co (USA - NJ) Sanofi Pasteur MSD (SPMSD)
Therapeutic area: Infectious diseases
Type agreement: joint-venture
Action mechanism:
Disease:
Details: * On January 2, 2017 , Sanofi and its vaccines global business unit Sanofi Pasteur confirmed the end of their vaccine joint-venture with Merck & Co, Sanofi Pasteur MSD (SPMSD). Sanofi Pasteur and MSD will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations. The change in operations took effect January 1, 2017. Each company will be able to define its own vaccines strategy to benefit public health and create value for patients, healthcare professionals, and payers. In November 2015, as part of its strategic roadmap 2020, Sanofi announced that it would reshape its portfolio, namely through sustained leadership in vaccines. * On November 23, 2016, Sanofi Pasteur and Merck & Co confirm that 31 December 2016 will be the official closing date of the end of their vaccine joint-venture Sanofi Pasteur MSD (SPMSD), following clearances recently granted by the European Commission. Beginning January 1st, 2017, Sanofi Pasteur and Merck & Co will separately pursue their own vaccine strategies in Europe, integrating their respective European vaccines business into their operations. SPMSD currently operates in 19 European countries. Since its announcement in March 2016, the project has been managed in an open dialogue with the SPMSD employees, unions and relevant external stakeholders, in compliance with the applicable rules and regulations. During the transitional period following the announcement of the ending of the joint-venture in March 2016, SPMSD and its shareholders have been focused on a smooth and orderly transition while achieving their public healthcare goals and upholding their commitments to their employees, customers and business partners. Sanofi Pasteur and MSD believe that reintegrating their respective vaccine portfolios into their companies’ operations will better position them to drive growth, execute more efficiently, optimize vaccine coverage and bring new vaccines to market more quickly. Each company will be able to define its own vaccines strategy to benefit public health and create value for patients, healthcare professionals, and payers. * On March 8, 2016, Sanofi Pasteur and Merck & Co announced their intent to end their joint vaccines operations in Europe. Upon concluding their joint venture, both companies plan to integrate their respective European vaccine businesses into their operations, independently manage their product portfolios and pursue their own distinct growth strategies in Europe. The joint venture Sanofi Pasteur MSD, owned on a 50/50 basis by Sanofi Pasteur and Merck & Co, was created in 1994 to develop and commercialize vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD’s development pipelines, addressing key unmet medical needs and helping to protect millions of lives.Sanofi Pasteur and MSD expect the project to be completed by the end of 2016, subject to local labor laws and regulations and regulatory approvals.
Financial terms:
Latest news:
